Charleston Laboratories, Inc. and co-development and commercialization partner, Daiichi Sankyo, Inc., have completed a pharmacokinetics study on CL-108, Charleston’s lead product in development for moderate to severe pain and the prevention of opioid-induced nausea and vomiting.
 
CL-108 is a tablet containing 7.5 mg of hydrocodone and 325 mg of acetaminophen with 12.5 mg of fast-absorbed promethazine. 
 
“This study demonstrated that CL-108 provides comparable bioavailability of hydrocodone, acetaminophen and promethazine to commercial products,” said Dr. Bernard Schachtel, chief scientific officer at Charleston Laboratories.